Truist Trims Insmed Price Target to $185 on Competitive Concerns
Truist reduced Insmed’s price target after adjusting estimates for BRINSUPRI amid rising competition and physician feedback. Truist cut its price target for Insmed (INSM) to $185 from $205 while maintaining a Buy rating. The adjustment follows Q1 2026 results and reflects